Quick Comparison
| LL-37 | Thymulin | |
|---|---|---|
| Half-Life | 4-6 hours (varies by tissue environment) | 1-2 hours |
| Typical Dosage | Research: 50-200 mcg subcutaneous once daily. Topical formulations also used for wound healing applications. No standardized clinical dosing established. | Research: 1-5 mg subcutaneous once daily. Anti-aging protocols: 1 mg subcutaneous once daily for 10-20 day courses. Zinc supplementation (15-30 mg zinc daily) recommended for full biological activity. Courses repeated 2-3 times yearly. |
| Administration | Subcutaneous injection or topical | Subcutaneous injection |
| Research Papers | 30 papers | 11 papers |
| Categories |
Mechanism of Action
LL-37
LL-37 is the only cathelicidin-derived antimicrobial peptide in humans, cleaved from the precursor protein hCAP-18 by proteinase 3 in neutrophil granules. It functions as a critical component of the innate immune system's first line of defense, with both direct antimicrobial activity and sophisticated immunomodulatory signaling.
The direct antimicrobial mechanism relies on LL-37's amphipathic alpha-helical structure — one face is positively charged (cationic) while the other is hydrophobic. The cationic face electrostatically attracts the negatively charged phospholipid headgroups of bacterial membranes (which differ from mammalian membranes in their lipid composition and charge distribution). Once bound, the hydrophobic face inserts into the lipid bilayer, creating pores or disrupting membrane integrity through a 'carpet' or 'toroidal pore' mechanism. This physical membrane disruption kills bacteria, fungi, and enveloped viruses rapidly and is difficult for microbes to develop resistance against, unlike conventional antibiotics that target specific enzymes.
The immunomodulatory functions are equally important. LL-37 acts as a chemoattractant for neutrophils, monocytes, and T cells through formyl peptide receptor-like 1 (FPRL1) activation, recruiting immune cells to infection sites. It promotes macrophage phagocytosis and enhances the killing capacity of neutrophil extracellular traps (NETs). Critically, LL-37 neutralizes bacterial lipopolysaccharide (LPS/endotoxin), preventing the cytokine storm that leads to sepsis. It also stimulates angiogenesis through VEGF upregulation and promotes wound re-epithelialization by activating epidermal growth factor receptor (EGFR) transactivation. LL-37 production is upregulated by vitamin D (which is why vitamin D status affects innate immunity), and its expression is found in skin, airways, the gastrointestinal tract, and virtually all epithelial barrier tissues.
Thymulin
Thymulin (also known as facteur thymique sérique, FTS) is a nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is unique among thymic hormones in requiring a zinc ion for biological activity. The zinc ion is coordinated by the asparagine (position 9), serine (position 4), and the N-terminal glutamic acid, creating a metallopeptide complex where the zinc is essential for the correct three-dimensional conformation needed for receptor binding. Without zinc, thymulin is biologically inactive — this zinc dependency has important implications for immune function in zinc-deficient individuals.
Thymulin is produced exclusively by thymic epithelial cells and is the only thymic hormone that is truly thymus-specific — its serum levels become undetectable after thymectomy (surgical thymus removal). It binds to high-affinity receptors on T-cell precursors (thymocytes) and mature T cells, promoting several key aspects of T-cell biology. It induces the expression of T-cell differentiation markers (CD2, CD3, CD4, CD8), driving immature thymocytes through the stages of T-cell maturation. It enhances the cytotoxic function of CD8+ T cells and the helper function of CD4+ T cells. It modulates the balance between T-helper and T-suppressor (regulatory) cell populations, promoting appropriate immune regulation.
Thymulin also modulates cytokine production — it promotes IL-2 secretion (essential for T-cell proliferation and the generation of effector T cells), enhances IFN-γ production (important for Th1 cellular immunity), and influences the balance of pro-inflammatory versus anti-inflammatory cytokines. Serum thymulin levels peak around puberty and decline progressively with age, becoming virtually undetectable by age 60 — mirroring the age-related involution of the thymus gland. This decline correlates closely with immunosenescence markers: reduced naive T-cell output, skewed CD4/CD8 ratios, impaired vaccine responses, and increased susceptibility to infections and cancer. Zinc supplementation alone can partially restore thymulin activity in zinc-deficient elderly individuals, highlighting the clinical importance of the zinc-thymulin interaction.
Risks & Safety
LL-37
Common
injection site inflammation, local redness and swelling.
Serious
at high doses it can worsen inflammation instead of calming it; may trigger or worsen autoimmune conditions like psoriasis, lupus, or atherosclerosis.
Rare
body-wide inflammatory response, allergic reactions. Effects depend on dose — low doses calm inflammation, high doses can increase it.
Thymulin
Common
injection site reactions, mild fatigue.
Serious
very limited human clinical data for supplemental use, may overstimulate immune system in autoimmune conditions.
Rare
allergic reactions.
Full Profiles
LL-37 →
The body's main antimicrobial peptide — a natural part of the immune system that fights bacteria, viruses, and fungi. Beyond fighting germs, it promotes wound healing, helps regulate inflammation, and stimulates new blood vessel growth at injury sites. The body makes it in response to infection or tissue damage. People use it for wound healing and immune support.
Thymulin →
A 9-amino-acid peptide naturally produced by the thymus gland that requires zinc to work properly. Distinct from Thymalin (which is a thymic extract mixture). Plays a central role in T-cell development, immune system regulation, and the zinc-thymulin axis that declines with aging. Thymulin levels decrease as the thymus shrinks with age, contributing to immune decline.